Anzeige
Mehr »
Mittwoch, 13.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JCLB | ISIN: FR0011049824 | Ticker-Symbol: 4ZG
Stuttgart
13.08.25 | 09:19
2,340 Euro
0,00 % 0,000
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIAN TECHNOLOGIES Chart 1 Jahr
5-Tage-Chart
MEDIAN TECHNOLOGIES 5-Tage-Chart
RealtimeGeldBriefZeit
2,2702,29010:13

Aktuelle News zur MEDIAN TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoMedian Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31, 2025219Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
01.08.Median Technologies Has Completed a Capital Increase of € 23.9 Million354Capital increase of 23.9 million euros from institutional and retail investors at a subscription price of €1.66 per ABSA Extension of the Company's cash runway until Q4 2026 Regulatory...
► Artikel lesen
23.07.Following the signature of a financial agreement for up to €37.5 million with the EIB, Median Technologies launches an approximately €22 million capital increase to support commercialization of eyonis LCS in the U.S. ...463Capital increase in the form of shares with attached warrants ("ABSA") without preferential subscription rights by way of an equity public offering and with a priority subscription period of 5...
► Artikel lesen
11.07.Median Technologies Signs Financial Agreement for up to €37.5 Million New Financing Facility With the European Investment Bank (EIB)404Regulatory News: Median Technologies FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis, a suite of artificial intelligence (AI) powered Software as...
► Artikel lesen
09.07.Median Technologies: Half Year Liquidity Contract Statement266Regulatory News: Under the liquidity contract entrusted by Median Technologies (PARIS: ALMDT, FR0011049824, ALMDT, PEA/SME eligible, "Median" or "the Company") to TP ICAP (Europe), the following...
► Artikel lesen
07.07.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2025242Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
MEDIAN TECHNOLOGIES Aktie jetzt für 0€ handeln
01.07.Median Technologies Files European Application for Class IIb CE Marking of Its AI-Based Software as a Medical Device for Lung Cancer Screening, eyonis LCS302Class IIb CE marking is a prerequisite for Median's eyonis LCS Software as a Medical Device marketing in Europe Lung cancer screening programs are already implemented in several European...
► Artikel lesen
10.06.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025269Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
28.05.Median Technologies announces the availability of the preparatory documents for the Shareholders' Ordinary and Extraordinary General Meeting on June 17, 2025373Regulatory News: The shareholders of Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, "Median" or "The Company") are invited to participate in the Shareholders' Ordinary and Extraordinary...
► Artikel lesen
27.05.Median Technologies to Showcase iCRO's Central and AI-Powered Imaging Services for Oncology Clinical Trials at ASCO 2025289Median is a leading provider of imaging services to the world's top oncology pharma companies ASCO abstracts position Median as highly differentiated provider of AI-imaging services for...
► Artikel lesen
16.05.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30, 2025321Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares ...
► Artikel lesen
14.05.Median Technologies submits U.S. application for 510(k) clearance of eyonis LCS299Submission based on positive data from two pivotal studies, which both met their primary endpoints U.S. clearance expected in Q3 2025 based on average observed review timelines for radiological...
► Artikel lesen
12.05.Median Technologies to Present Scientific Posters on eyonis LCS in Two Major Health Conferences in North America in May 2025290Projected economic benefits of using AI-powered detection/diagnostic Software as a Medical Device, like eyonis® LCS, will be presented at ISPOR 2025, the annual conference of the leading professional...
► Artikel lesen
06.05.Median Technologies to Participate in Several Investor Conferences in May and June 2025362Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis, a suite of artificial intelligence (AI) powered Software...
► Artikel lesen
29.04.Median Technologies Reports Full-year 2024 Financial Results403Returns to FY revenue growth in 2024 (+3.3%), with acceleration in H2 (+10.2%) Slight decrease in operating loss, from €23.1 million in 2023 to €22.5 million in 2024 Operational...
► Artikel lesen
24.04.Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements391€6.0 million in Q1 2025 revenues, up 11% over Q1 2024 €74.8 million all-time high order backlog as of March 31, 2025 eyonis LCS pivotal RELIVE study met all key endpoints U.S....
► Artikel lesen
07.04.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31, 2025207Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares ...
► Artikel lesen
31.03.eyonis LCS, Median Technologies' AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study335All secondary endpoints required to support eyonis LCS' intended use and desired marketing claims achieved in RELIVE eyonis LCS previously met primary endpoint, achieving statistically...
► Artikel lesen
07.03.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of February 28, 2025388Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares ...
► Artikel lesen
03.03.Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders' Extraordinary General Meeting on March 20, 2025298Regulatory News: The shareholders of Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, "Median" or "The Company") are invited to participate in the Shareholders' Extraordinary...
► Artikel lesen
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1